Merck Sharp + Dohme Corp.

Other

Merck + Co., Inc.

Chinese Academy of Sciences

Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.

Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.

Scios Inc.

Merck Sharpe & Dohme Corp.

Sunnylife Pharma, Inc.

Brivu Technologies Co., Ltd

Wyeth

Zhijian Lu

Peter J Sinclair

Amjad Ali

Christopher Francis Thompson

Cameron James Smith

Xibin Liao

Yi-Heng Chen

Jia Tao Li

James R Tata

Yubo Zhou

Anhui Gao

Hong Li

Qiaolin Deng

Gayle E Taylor

Nazia Quraishi

Yusheng Xiong

Hyewon Youm

Jason Eugene Imbriglio

Arthur A Patchett

Subharekha Raghavan

Babu J Mavunkel

Clare London

Donald J Kyle

Thomas A Rano

Julianne A Hunt

Ming You

Joann M Napolitano

Joann Bohn

Adrian A Dowst

Tracy Huening

Lihu Yang

Ravi P Nargund

Yuan Cheng

Rui Liang

David Askin

Kevin Tyler Chapman

Richard John Varsolona

XiaoXia Qian

Wanying Sun

Wonsuk Chang

Ramzi Farah Sweis

Petr Vachal

Nancy J Kevin

Joseph Leslie Duffy

Scott B Hoyt

Guizhen Dong

Mark G Charest

Mu T Wu

Fengqi Zhang

R Scott Hoerrner

Meng Hsin Chen

Jerry Andrew Taylor

Debra L Ondeyka

Kake Zhao

Xiaotian Zhong

Stephen H Herrmann

Joseph D Armstrong, Iii

Jonathan A Groeper

Ronald William Kriz

Yijie Gao

Florida Kallashi

Brian Anthony Kirk

Robert M Purick

Nicole M Piche

Mei Geng

Whitney Lane Petrilli

Fred Fleitz

Daniel E Petrillo

Zhe Feng

Xing Yang

Yarong Zhang

Yunsheng Yang

Sarjavit Chakravarty

Samantha E Adamson

Gayle E Hallett

Xiaoxia Qian

Jia Li

Hye Won Youm

Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Bruton's tyrosine kinase inhibitors

Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I): 

The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, X, Y, R, R, R, Rand n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples. 

Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders

Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HTreceptor, and, in particular, are selective agonists of the mammalian 5-HTreceptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HTreceptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation. 

[object Object]

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ('DGAT2') and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. 

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

This disclosure provides a method for manufacturing a large-version light guide sheet using a mask plate. The method includes adopting a mask plate containing a plurality of regions, performing selective polymerization on a photopolymerizable material mixture which is coated on a large-version light guide substrate () by means of the mask plate, and forming a raised or depressed microstructure () on the large-version light guide substrate (), so as to constitute a large-version light guide sheet. The large-version light guide sheet comprises a plurality of units (U, U, U, U). By dividing the large-version light guide sheet, a plurality of discrete unit light guide sheets that are used for an LCD backlight source and an LED lighting assembly are obtained. The method overcomes the limitations of ink jet printing, injection molding, laser etching and other technologies, and improves the production rate of high-performance thinned light guide sheets.

Method for manufacturing large-size light-guide sheet by using mask

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ('DGAT2') and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio-renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. 

Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a &#x2014;CH&#x2014;.

CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. 

1,3-oxazolidin -2-one derivatives useful as CETP inhibitors

A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.

Optical diffusers, photomasks and their methods of fabrication

Growing community of inventors

Clinton, NJ, United States of America

Zhijian Lu